SCM
KZIA

Stonepine Capital Management’s Kazia Therapeutics KZIA Stock Holding History

Stonepine Capital Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Hold
345,179
– – 2.74% 11
2026
Q1 		$2.57M Sell
345,179
-115,180
-25% -$802K 1.03% 15
2025
Q4 		$3.17M Buy
+460,359
New +$3.92M 2.32% 10

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Stonepine Capital Management's KZIA Position: Q2 2026 in Review

Stonepine Capital Management held its Kazia Therapeutics (KZIA) position steady in Q2 2026 at 345,179 shares worth $4.86M. The position accounts for 2.74% of the portfolio, ranked #11.

Stonepine Capital Management first reported a position in KZIA in Q4 2025 and has held it in 3 quarters since. 36 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Stonepine Capital Management held 345,179 shares of Kazia Therapeutics worth $4.86M as of Q2 2026.
  • Stonepine Capital Management left its Kazia Therapeutics share count unchanged in Q2 2026.
  • Kazia Therapeutics made up 2.74% of Stonepine Capital Management's portfolio in Q2 2026, its #11 holding.
  • Stonepine Capital Management first reported a position in Kazia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 36 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.